In cases having ER-positive, HER2-positive disease, 51% of the panelists agreed to give anti-HER2 therapy in case of tumor size equal or more than 5 mm or 6 mm (30% of votes), but 19% suggest giving such treatment in smaller lesions. The gene discussed is ERBB2; the disease is neoplasm.